Special Issue "Treatment of Bipolar Depression"
Deadline for manuscript submissions: 31 May 2019
Dr. Carmine Tomasetti
Dr. Domenico De Berardis
National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4, Teramo, Italy; Chair of Psychiatry, University “G. d’Annunzio” of Chieti-Pescara, Italy; Polyedra Research Group, Italy
Website | E-Mail
Interests: bipolar disorder; psychopharmacology; antipsychotics; schizophrenia; functional neuroimaging; psychopathology
On behalf of the Journal of Clinical Medicine (JCM) editorial team, we are delighted to present a new Special Issue on the topic of “Treatment of Bipolar Depression”, guest edited by Dr. Carmine Tomasetti and Dr. Domenico De Berardis.
In terms of neuropsychiatric diseases, Bipolar Disorder (BD) is one of the main contributors to chronic disability throughout the world. The World Health Organization established that BD represents the 17th biggest cause of years lived with disability (YLD) in Europe with 1.6% of the total population affected (source: Global Health Estimates 2014 Summary Tables. YLD by cause, age and sex, by WHO Region, 2000–2012). Intrinsically, BD is characterized by highly unstable mood and recurring episodes, which are poorly responsive to current available treatment strategies. Indeed, although monotherapy is suggested, the use of several, often unapproved, therapeutic combinations seems the rule. Bipolar depression is particularly unresponsive to treatments. In fact, if globally bipolar patients remain ill in 50% of follow-ups after onset, then 75% of those unresponsive patients are depressed. Hence, many cases, above all amongst bipolar depressive patients, may be considered “treatment resistant”. To date, scientific evidence points out some encouraging strategies based on pharmacotherapeutic add-ons or experimental treatments. However, more and more precise and systematic studies are needed in order to shed light on this intricate argument.
The present Special Issue aims at deepening the present knowledge on clinical treatment approaches to Bipolar Depression, based on the ultimate neurobiological physiopathogenetic scientific evidence. This issue will cover the most recent advances in Bipolar Depression treatment strategies, in order to provide a useful tool to address the most fitting therapies for these complex cases in everyday clinical practice.Dr. Carmine Tomasetti
Dr. Domenico De Berardis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Bipolar Disorder
- Mood stabilizers
- New experimental treatments
- Phases of Bipolar Disorder
- Maintenance strategies